Anti-Fibrinolytic Drugs - Brazil

Brazil

The Anti-Fibrinolytic Drugs market in Brazil is expected to see a significant increase in revenue in the coming years.
By 2024, the projected revenue is estimated to reach €293.70m.
Furthermore, the market is anticipated to demonstrate a steady annual growth rate (CAGR 2024-2029) of 5.31%, ultimately resulting in a market volume of €380.50m by 2029.
In comparison to other countries, United States is projected to generate the highest revenue, reaching €9,141.00m in 2024.
Brazil is witnessing a surge in the demand for anti-fibrinolytic drugs as the country experiences an increase in surgical procedures and cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Brazil has been experiencing significant growth in recent years.

Customer preferences: There is a growing demand for Anti-Fibrinolytic Drugs in Brazil due to the increasing prevalence of bleeding disorders such as hemophilia and von Willebrand disease. Additionally, the aging population in Brazil has also contributed to the rising demand for these drugs as older individuals are more susceptible to bleeding disorders.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Brazil is the increasing use of these drugs in surgical procedures. With the rising number of surgeries being performed in Brazil, there has been a corresponding increase in the use of Anti-Fibrinolytic Drugs to prevent excessive bleeding during and after surgery. Another trend in the market is the growing preference for topical Anti-Fibrinolytic Drugs over systemic drugs, as they are more effective in controlling bleeding at the site of injury.

Local special circumstances: Brazil has a well-established healthcare system that provides universal access to healthcare services to its citizens. This has helped to increase the availability and accessibility of Anti-Fibrinolytic Drugs in the country. Additionally, the Brazilian government has implemented several policies to promote the use of generic drugs, which has helped to reduce the cost of Anti-Fibrinolytic Drugs and increase their affordability.

Underlying macroeconomic factors: The Brazilian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has helped to drive the growth of the Anti-Fibrinolytic Drugs market in the country. Additionally, the Brazilian government has implemented several measures to promote the development of the pharmaceutical industry, which has helped to increase the production and availability of Anti-Fibrinolytic Drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.